Inventing New Possibilities, Transforming Treatment Paradigms
Kymera Therapeutics is a biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to improve the lives of patients with serious diseases. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD.
Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development.